DK0951466T3 - Cycloalkyl-, lactam, lacton- og beslægtede forbindelser, farmaceutiske sammensætninger, der omfatter samme, og fremgangsmåder til inhibering af beta-amyloidpeptidfrigivelse og/eller dets syntese ved anvendelse af sådanne forbindelser - Google Patents

Cycloalkyl-, lactam, lacton- og beslægtede forbindelser, farmaceutiske sammensætninger, der omfatter samme, og fremgangsmåder til inhibering af beta-amyloidpeptidfrigivelse og/eller dets syntese ved anvendelse af sådanne forbindelser

Info

Publication number: DK0951466T3
Authority: DK; Denmark
Prior art keywords: compounds; lactam; lactone; cycloalkyl; synthesis
Prior art date: 1996-12-23

Application number

DK97953208T

Other languages

English (en)

Inventor

Jing Wu

Michael A Pleiss

Varghese John

Stephen Freedman

Bruce A Dressman

Jay S Tung

Eugene D Thorsett

Jeffrey S Nissen

Jeffrey Neitz

Lee H Latimer

Thomas C Britton

James E Audia

Jon K Reel

Thomas E Mabry

Cynthia L Cwi

James J Droste

Steven S Henry

Stacey L Mcdaniel

William L Scott

Russell D Stucky

Warren J Porter

Original Assignee

Elan Pharm Inc

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-12-23

Filing date

1997-12-22

Publication date

2009-03-16

1997-12-22 Application filed by Elan Pharm Inc, Lilly Co Eli filed Critical Elan Pharm Inc

2009-03-16 Application granted granted Critical

2009-03-16 Publication of DK0951466T3 publication Critical patent/DK0951466T3/da

Links

150000001875 compounds Chemical class 0.000 title 2
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 title 1
230000015572 biosynthetic process Effects 0.000 title 1
125000000753 cycloalkyl group Chemical group 0.000 title 1
230000002401 inhibitory effect Effects 0.000 title 1
150000003951 lactams Chemical class 0.000 title 1
150000002596 lactones Chemical class 0.000 title 1
238000000034 method Methods 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
238000003786 synthesis reaction Methods 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
- C07D311/82—Xanthenes
- C07D311/90—Xanthenes with hydrocarbon radicals, substituted by amino radicals, directly attached in position 9
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/08—Oxygen atoms
- C07D223/10—Oxygen atoms attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/32—All rings being cycloaliphatic the ring system containing at least eleven carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/30—Ortho- or ortho- and peri-condensed systems containing three rings containing seven-membered rings
- C07C2603/32—Dibenzocycloheptenes; Hydrogenated dibenzocycloheptenes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Pharmacology & Pharmacy (AREA)
Genetics & Genomics (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Gastroenterology & Hepatology (AREA)
Hospice & Palliative Care (AREA)
Epidemiology (AREA)
Virology (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK97953208T 1996-12-23 1997-12-22 Cycloalkyl-, lactam, lacton- og beslægtede forbindelser, farmaceutiske sammensætninger, der omfatter samme, og fremgangsmåder til inhibering af beta-amyloidpeptidfrigivelse og/eller dets syntese ved anvendelse af sådanne forbindelser DK0951466T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US78002596A	1996-12-23	1996-12-23
PCT/US1997/022986 WO1998028268A2 (en)	1996-12-23	1997-12-22	CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AS β-AMYLOID PEPTIDE RELEASE INHIBITORS

Publications (1)

Publication Number	Publication Date
DK0951466T3 true DK0951466T3 (da)	2009-03-16

Family

ID=25118329

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK97953208T DK0951466T3 (da)	1996-12-23	1997-12-22	Cycloalkyl-, lactam, lacton- og beslægtede forbindelser, farmaceutiske sammensætninger, der omfatter samme, og fremgangsmåder til inhibering af beta-amyloidpeptidfrigivelse og/eller dets syntese ved anvendelse af sådanne forbindelser

Country Status (28)

Country	Link
EP (1)	EP0951466B1 (da)
JP (1)	JP3812952B2 (da)
KR (1)	KR20000069654A (da)
CN (2)	CN1616432A (da)
AR (1)	AR010854A1 (da)
AT (1)	ATE421509T1 (da)
AU (1)	AU749658C (da)
BR (1)	BR9714517A (da)
CA (1)	CA2272305A1 (da)
CO (1)	CO4930282A1 (da)
DE (1)	DE69739236D1 (da)
DK (1)	DK0951466T3 (da)
EA (1)	EA002100B1 (da)
ES (1)	ES2319239T3 (da)
HR (1)	HRP970705A2 (da)
HU (1)	HUP0001232A3 (da)
ID (1)	ID22177A (da)
IL (2)	IL158355A0 (da)
NO (1)	NO993098L (da)
NZ (1)	NZ335583A (da)
PE (1)	PE52799A1 (da)
PL (1)	PL196641B1 (da)
PT (1)	PT951466E (da)
SI (1)	SI0951466T1 (da)
TR (1)	TR199901343T2 (da)
TW (1)	TW568914B (da)
WO (1)	WO1998028268A2 (da)
ZA (1)	ZA9711537B (da)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6635632B1 (en)	1996-12-23	2003-10-21	Athena Neurosciences, Inc.	Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
KR20010033408A (ko) *	1997-12-22	2001-04-25	진 엠. 듀발	폴리시클릭 α-아미노-ε-카프롤락탐 및 관련 화합물
US6528505B1 (en)	1998-06-22	2003-03-04	Elan Pharmaceuticals, Inc.	Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6509331B1 (en)	1998-06-22	2003-01-21	Elan Pharmaceuticals, Inc.	Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6569851B1 (en)	1998-06-22	2003-05-27	Elan Pharmaceutials, Inc.	Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6958330B1 (en)	1998-06-22	2005-10-25	Elan Pharmaceuticals, Inc.	Polycyclic α-amino-ε-caprolactams and related compounds
US6774125B2 (en)	1998-06-22	2004-08-10	Elan Pharmaceuticals, Inc.	Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6552013B1 (en)	1998-06-22	2003-04-22	Elan Pharmaceuticals, Inc.	Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
NZ525513A (en)	1998-08-07	2004-09-24	Pont Pharmaceuticals Du	Succinoylamino lactams as inhibitors of Abeta protein production
HRP990246A2 (en) *	1998-08-07	2000-06-30	Du Pont Pharm Co	Succinoylamino benzodiazepines as inhibitors of a beta protein production
US6486350B1 (en)	1998-09-30	2002-11-26	Elan Pharmaceuticals Inc.	Biological reagents and methods for determining the mechanism in the generation of β-amyloid peptide
US6737038B1 (en)	1998-11-12	2004-05-18	Bristol-Myers Squibb Company	Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
EP1313426A2 (en)	1998-12-24	2003-05-28	Bristol-Myers Squibb Pharma Company	Succinoylamino benzodiazepines as inhibitors of a-beta protein production
JP2003503476A (ja)	1999-07-06	2003-01-28	バーテックスファーマシューティカルズインコーポレイテッド	環化アミド誘導体
MXPA02001340A (es) *	1999-08-05	2004-07-16	Prescient Neuropharma Inc	Compuestos novedosos 1,4-benzodiazepina y derivados de los mismos.
US6503902B2 (en)	1999-09-13	2003-01-07	Bristol-Myers Squibb Pharma Company	Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
CA2377221A1 (en)	1999-09-13	2001-03-22	Bristol-Myers Squibb Pharma Company	Hydroxyalkanoyl aminolactams and related structures as inhibitors of a.beta. protein production
US6960576B2 (en)	1999-09-13	2005-11-01	Bristol-Myers Squibb Pharma Company	Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
WO2001027108A1 (en)	1999-10-08	2001-04-19	Bristol-Myers Squibb Pharma Company	AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
JP2003513958A (ja) *	1999-11-09	2003-04-15	イーライ・リリー・アンド・カンパニー	β−アミロイドペプチド放出および／またはその合成を阻害するために有用なβ−アミノ酸化合物
US6525044B2 (en)	2000-02-17	2003-02-25	Bristol-Myers Squibb Company	Succinoylamino carbocycles and heterocycles as inhibitors of a-β protein production
EP1267906A1 (en) *	2000-03-28	2003-01-02	Bristol-Myers Squibb Pharma Company	Lactams as inhibitors of a-beta protein production
US6495540B2 (en)	2000-03-28	2002-12-17	Bristol - Myers Squibb Pharma Company	Lactams as inhibitors of A-β protein production
CN1436175A (zh)	2000-04-03	2003-08-13	布里斯托尔-迈尔斯斯奎布药品公司	作为Aβ－蛋白生产抑制剂的环状内酰胺
JP2004508289A (ja) *	2000-04-03	2004-03-18	デュポン　ファーマシューティカルズ　カンパニー	Ａβタンパク質産生の阻害剤としての環状ラクタム
CA2404273A1 (en)	2000-04-11	2001-10-18	Bristol-Myers Squibb Pharma Company	Substituted lactams as inhibitors of a.beta. protein production
US6878363B2 (en)	2000-05-17	2005-04-12	Bristol-Myers Squibb Pharma Company	Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
GB0012671D0 (en)	2000-05-24	2000-07-19	Merck Sharp & Dohme	Therapeutic agents
EP1268450A1 (en)	2000-06-01	2003-01-02	Bristol-Myers Squibb Pharma Company	Lactams substituted by cyclic succinates as inhibitors of a-beta protein production
US6432944B1 (en)	2000-07-06	2002-08-13	Bristol-Myers Squibb Company	Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives
GB0025173D0 (en)	2000-10-13	2000-11-29	Merck Sharp & Dohme	Therapeutic agents
US7468365B2 (en)	2000-11-17	2008-12-23	Eli Lilly And Company	Lactam compound
UA74849C2 (en) *	2000-11-17	2006-02-15	Lilly Co Eli	Lactam
UA77165C2 (en) *	2000-11-17	2006-11-15	Lilly Co Eli	(n)-((s)-2-hydroxy-3-methyl-butyryl)-1-(l-alaninyl)-(s)-1-amino-3-methyl-4,5,6,7-tetrahydro-2h-3-benzazepin-2-one dihydrate, processes for manufacturing and pharmaceutical composition
CA2425558C (en) *	2000-11-17	2012-01-03	Eli Lilly And Company	Lactam compound
JP2004520365A (ja)	2001-01-17	2004-07-08	アミュラテラピューティクスリミテッド	クルジパインおよび他のシステインプロテアーゼの阻害剤
US7132449B2 (en)	2001-01-17	2006-11-07	Amura Therapeutics Limited	Inhibitors of cruzipain and other cysteine proteases
US7425562B2 (en)	2001-01-17	2008-09-16	Amura Therapeutics Ltd.	Inhibitors of cruzipain and other cysteine proteases
EP1362042A1 (en) *	2001-01-17	2003-11-19	Amura Therapeutics Limited	Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases
FR2840899B1 (fr) *	2002-06-12	2005-02-25	Sanofi Synthelabo	Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique
AR039059A1 (es)	2001-08-06	2005-02-09	Sanofi Aventis	Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
TW200502221A (en)	2002-10-03	2005-01-16	Astrazeneca Ab	Novel lactams and uses thereof
CA2505361A1 (en) *	2002-11-11	2004-05-27	Bayer Healthcare Ag	Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist
ATE496893T1 (de)	2002-12-20	2011-02-15	X Ceptor Therapeutics Inc	Isochinolinonderivate und deren verwendung als medikamente
FR2850380B1 (fr) *	2003-01-23	2006-07-07	Sanofi Synthelabo	Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique
EP1636196A1 (en)	2003-03-14	2006-03-22	AstraZeneca AB	Novel lactams and uses thereof
ATE410161T1 (de)	2003-05-02	2008-10-15	Elan Pharm Inc	4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3- carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen
ITMI20032278A1 (it)	2003-11-21	2005-05-22	Ethicon Endo Surgery Inc	Dispositivo di diagnosi
SI1691814T1 (sl) *	2003-12-01	2012-11-30	Cambridge Entpr Ltd	Protivnetna zdravila
AU2005217596B2 (en)	2004-02-23	2012-01-19	Eli Lilly And Company	Anti-ABeta antibody
EP1802303B1 (en)	2004-09-17	2011-11-02	Whitehead Institute For Biomedical Research	Compounds, compositions and methods of inhibiting a-synuclein toxicity
JP4519621B2 (ja) *	2004-11-30	2010-08-04	アイバイツ株式会社	光酸発生剤および感光性樹脂組成物
EP2094836B1 (en)	2006-11-15	2016-06-08	Massachusetts Eye & Ear Infirmary	Generation of inner ear cells
CA2676715A1 (en)	2007-02-12	2008-08-21	Merck & Co., Inc.	Piperazine derivatives for treatment of ad and related conditions
CN101284828B (zh) *	2007-04-12	2011-04-27	中国科学院上海药物研究所	环庚烷并吡啶类化合物、其制备方法、用途及包含此类化合物的药物组合物
MX2010001754A (es)	2007-08-14	2010-05-14	Lilly Co Eli	Derivados de azepina como inhibidores de gamma secretasa.
KR101595238B1 (ko)	2007-12-21	2016-02-18	리간드 파마슈티칼스 인코포레이티드	선택적 안드로겐 수용체 조절제(ｓａｒｍ) 및 이의 용도
WO2009128057A2 (en)	2008-04-18	2009-10-22	UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al	Psycho-pharmaceuticals
US9776963B2 (en)	2008-11-10	2017-10-03	The Trustees Of The University Of Pennsylvania	Small molecule CD4 mimetics and uses thereof
WO2010060088A2 (en)	2008-11-24	2010-05-27	Massachusetts Eye & Ear Infirmary	Pathways to generate hair cells
CA2749700A1 (en) *	2009-01-23	2010-07-29	Msd K.K.	Benzodiazepin-2-on derivatives
US20120015938A1 (en) *	2009-02-17	2012-01-19	Msd K.K.	1,4-benzodiazepin-2-on derivatives
AR079170A1 (es)	2009-12-10	2011-12-28	Lilly Co Eli	Compuesto de ciclopropil-benzamida-imidazo-benzazepina inhibidor de diacil-glicerol aciltransferasa, sal del mismo, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de obesidad o para mejorar la sensibilidad a insulina y compuesto intermedio par
US8486967B2 (en) *	2010-02-17	2013-07-16	Hoffmann-La Roche Inc.	Heteroaryl substituted piperidines
AR084070A1 (es)	2010-12-02	2013-04-17	Constellation Pharmaceuticals Inc	Inhibidores del bromodominio y usos de los mismos
US9249161B2 (en)	2010-12-02	2016-02-02	Constellation Pharmaceuticals, Inc.	Bromodomain inhibitors and uses thereof
WO2012151512A2 (en)	2011-05-04	2012-11-08	Constellation Pharmaceuticals, Inc.	Bromodomain inhibitors and uses thereof
EP2721031B1 (en)	2011-06-17	2016-01-20	Constellation Pharmaceuticals, Inc.	Bromodomain inhibitors and uses thereof
AR087107A1 (es) *	2011-07-27	2014-02-12	Lilly Co Eli	Compuesto inhibidor de la señalizacion de la trayectoria notch
WO2013090696A1 (en)	2011-12-14	2013-06-20	Dana-Farber Cancer Institute, Inc.	Cd4-mimetic inhibitors of hiv-1 entry and methods of use thereof
TWI602820B (zh)	2012-06-06	2017-10-21	星宿藥物公司	溴域抑制劑及其用途
EP2864336B1 (en)	2012-06-06	2016-11-23	Constellation Pharmaceuticals, Inc.	Benzo[b]isoxazoloazepine bromodomain inhibitors and uses thereof
CA2883896C (en)	2012-09-07	2023-03-07	Massachusetts Eye & Ear Infirmary	Treating hearing loss
CA2884309A1 (en)	2012-09-07	2014-03-13	Massachusetts Eye And Ear Infirmary	Methods and compositions for regenerating hair cells and/or supporting cells from differentiated cochlear cells or differentiated utricular cells by modulation of notch and cmyc activity
CN103435549A (zh) *	2013-08-14	2013-12-11	无锡惠飞生物医药技术有限公司	5-甲基-7-氨基-5H,7H-二苯并[b,d]氮杂环庚-6-酮的制备方法
EP3094323A4 (en)	2014-01-17	2017-10-11	Ligand Pharmaceuticals Incorporated	Methods and compositions for modulating hormone levels
CA2952830C (en)	2014-06-20	2022-11-01	Constellation Pharmaceuticals, Inc.	Crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide
WO2016022776A2 (en)	2014-08-06	2016-02-11	Massachusetts Eye And Ear Infirmary	Increasing atoh1 life to drive sensorineural hair cell differentiantion
US9975848B2 (en)	2014-08-13	2018-05-22	The Trustees Of The University Of Pennsylvania	Inhibitors of HIV-1 entry and methods of use thereof
EP3212773B1 (en)	2014-10-29	2021-09-15	Massachusetts Eye and Ear Infirmary	Efficient delivery of therapeutic molecules to cells of the inner ear
TWI609687B (zh)	2015-04-14	2018-01-01	美國禮來大藥廠	平滑肌肉瘤之標靶性治療
WO2017096233A1 (en)	2015-12-04	2017-06-08	Massachusetts Eye And Ear Infirmary	Treatment of hearing loss by inhibition of casein kinase 1
CN109219439B (zh)	2016-01-29	2022-09-20	马萨诸塞眼科耳科诊所	内耳支持细胞的扩增和分化及其使用方法
WO2017180385A1 (en)	2016-04-12	2017-10-19	Eli Lilly And Company	Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer
ES2881801T3 (es)	2016-04-12	2021-11-30	Lilly Co Eli	Terapia de combinación con inhibidores de Notch y CDK4/6 para su uso en el tratamiento de cáncer de pulmón
JP6840774B2 (ja)	2016-05-16	2021-03-10	ザジェネラルホスピタルコーポレイション	肺上皮エンジニアリングにおけるヒト気道幹細胞
MA45025A (fr)	2016-05-20	2019-03-27	Lilly Co Eli	Traitement d'association utilisant des inhibiteurs de notch et de pd-1 ou pd-l1
CN106243050B (zh) *	2016-08-10	2019-09-06	安徽恒星制药有限公司	一种适合工业化生产氯巴占的方法
US11376259B2 (en)	2016-10-12	2022-07-05	Eli Lilly And Company	Targeted treatment of mature T-cell lymphoma
MX390370B (es)	2016-12-16	2025-03-20	Pipeline Therapeutics Inc	Metodos para tratar la sinaptopatia coclear
IL268349B2 (en)	2017-02-17	2024-08-01	Hutchinson Fred Cancer Res	Combination therapies for treatment of bcma-related cancers and autoimmune disorders
SG11202003427XA (en)	2017-11-06	2020-05-28	Juno Therapeutics Inc	Combination of a cell therapy and a gamma secretase inhibitor
WO2019148067A1 (en)	2018-01-26	2019-08-01	Massachusetts Eye And Ear Infirmary	Treatment of hearing loss
AU2020257397B2 (en)	2019-04-19	2026-02-26	Ligand Pharmaceuticals Inc.	Crystalline forms and methods of producing crystalline forms of a compound
CN113754616B (zh) *	2021-09-27	2023-07-18	北京工商大学	一种反式-3-苯硫基-γ-内酯的制备方法
CN115656356B (zh) *	2022-09-30	2025-03-21	南京正济医药研究有限公司	4-羟基-7-苯氧基异喹啉-3-甲酸甲酯及其有关物质的测定方法
CN116116396B (zh) *	2023-02-20	2023-11-14	哈尔滨工程大学	一种偕胺肟基凝胶/氧化石墨/海绵复合材料的制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE42215B1 (en) *	1973-12-28	1980-07-02	Fujisawa Pharmaceutical Co	Azetidinone derivatives and process for preparation thereof
FR2278335A1 (fr) *	1974-07-04	1976-02-13	Fujisawa Pharmaceutical Co	Derives d'azetidinones et leurs procedes de preparation
NZ264143A (en) *	1993-08-09	1996-11-26	Lilly Co Eli	Use of an aspartyl protease inhibitor to inhibit beta-amyloid peptide production
US5580979A (en) *	1994-03-15	1996-12-03	Trustees Of Tufts University	Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions
US6251928B1 (en) *	1994-03-16	2001-06-26	Eli Lilly And Company	Treatment of alzheimer's disease employing inhibitors of cathepsin D
US5849691A (en) *	1996-02-20	1998-12-15	The United States Of America As Represented By The Department Of Health And Human Services	Peptidomimetic inhibitors of cathepsin D and plasmepsins I and II

1997
- 1997-12-22 EA EA199900593A patent/EA002100B1/ru not_active IP Right Cessation
- 1997-12-22 AU AU57007/98A patent/AU749658C/en not_active Ceased
- 1997-12-22 CN CNA2004100578889A patent/CN1616432A/zh active Pending
- 1997-12-22 KR KR1019997005677A patent/KR20000069654A/ko not_active Ceased
- 1997-12-22 ES ES97953208T patent/ES2319239T3/es not_active Expired - Lifetime
- 1997-12-22 IL IL15835597A patent/IL158355A0/xx unknown
- 1997-12-22 DK DK97953208T patent/DK0951466T3/da active
- 1997-12-22 ZA ZA9711537A patent/ZA9711537B/xx unknown
- 1997-12-22 HU HU0001232A patent/HUP0001232A3/hu unknown
- 1997-12-22 WO PCT/US1997/022986 patent/WO1998028268A2/en not_active Ceased
- 1997-12-22 EP EP97953208A patent/EP0951466B1/en not_active Expired - Lifetime
- 1997-12-22 ID IDW990563A patent/ID22177A/id unknown
- 1997-12-22 CA CA002272305A patent/CA2272305A1/en not_active Abandoned
- 1997-12-22 PL PL334305A patent/PL196641B1/pl unknown
- 1997-12-22 CN CNB971809011A patent/CN1171878C/zh not_active Expired - Fee Related
- 1997-12-22 NZ NZ335583A patent/NZ335583A/en unknown
- 1997-12-22 JP JP52886798A patent/JP3812952B2/ja not_active Expired - Fee Related
- 1997-12-22 BR BR9714517-3A patent/BR9714517A/pt not_active IP Right Cessation
- 1997-12-22 DE DE69739236T patent/DE69739236D1/de not_active Expired - Lifetime
- 1997-12-22 SI SI9730787T patent/SI0951466T1/sl unknown
- 1997-12-22 IL IL12982097A patent/IL129820A0/xx unknown
- 1997-12-22 TR TR1999/01343T patent/TR199901343T2/xx unknown
- 1997-12-22 HR HR08/780,025A patent/HRP970705A2/hr not_active Application Discontinuation
- 1997-12-22 PT PT97953208T patent/PT951466E/pt unknown
- 1997-12-22 AT AT97953208T patent/ATE421509T1/de active
- 1997-12-23 CO CO97074775A patent/CO4930282A1/es unknown
- 1997-12-23 PE PE1997001158A patent/PE52799A1/es not_active Application Discontinuation
- 1997-12-23 AR ARP970106159A patent/AR010854A1/es unknown
- 1997-12-23 TW TW086119638A patent/TW568914B/zh not_active IP Right Cessation
1999
- 1999-06-22 NO NO993098A patent/NO993098L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
HUP0001232A3 (en)	2001-02-28
JP2000511932A (ja)	2000-09-12
CN1171878C (zh)	2004-10-20
IL158355A0 (en)	2004-05-12
SI0951466T1 (sl)	2009-10-31
EP0951466A2 (en)	1999-10-27
PL334305A1 (en)	2000-02-14
HUP0001232A2 (hu)	2000-10-28
KR20000069654A (ko)	2000-11-25
AU749658B2 (en)	2002-06-27
PT951466E (pt)	2009-04-09
AU5700798A (en)	1998-07-17
CA2272305A1 (en)	1998-07-02
AU749658C (en)	2004-04-29
PL196641B1 (pl)	2008-01-31
DE69739236D1 (de)	2009-03-12
EA199900593A1 (ru)	2000-02-28
ES2319239T3 (es)	2009-05-05
NZ335583A (en)	2001-03-30
WO1998028268A3 (en)	1998-10-08
NO993098L (no)	1999-08-20
ID22177A (id)	1999-09-09
ZA9711537B (en)	1998-06-25
IL129820A0 (en)	2000-02-29
JP3812952B2 (ja)	2006-08-23
AR010854A1 (es)	2000-07-12
BR9714517A (pt)	2000-07-04
CN1242007A (zh)	2000-01-19
TR199901343T2 (xx)	1999-09-21
EP0951466B1 (en)	2009-01-21
NO993098D0 (no)	1999-06-22
ATE421509T1 (de)	2009-02-15
HRP970705A2 (en)	1998-10-31
TW568914B (en)	2004-01-01
WO1998028268A2 (en)	1998-07-02
PE52799A1 (es)	1999-05-27
EA002100B1 (ru)	2001-12-24
CO4930282A1 (es)	2000-06-27
CN1616432A (zh)	2005-05-18

Publication	Publication Date	Title
DK0951466T3 (da)	2009-03-16	Cycloalkyl-, lactam, lacton- og beslægtede forbindelser, farmaceutiske sammensætninger, der omfatter samme, og fremgangsmåder til inhibering af beta-amyloidpeptidfrigivelse og/eller dets syntese ved anvendelse af sådanne forbindelser
NO985578D0 (no)	1998-11-27	Magnesiumdiklorid-alkohol-addukter, fremgangsmÕte for fremstilling av slike, og katalysatorbestanddeler fremstilt av slike
ZA975947B (en)	1998-05-11	Aqueous-based pharmaceutical composition.
IL129083A0 (en)	2000-02-17	Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis
IL133420A0 (en)	2001-04-30	Pharmaceutical composition for combination of piperidinoalkanol-decongestant
DK0800383T3 (da)	2003-07-07	Farmaceutisk præparat, der omfatter proliposompulver til inhalation
ZA9710927B (en)	1998-06-15	Pharmaceutical composition.
ZA9710071B (en)	1998-05-25	Pharmaceutical composition.
IL133605A0 (en)	2001-04-30	Solid pharmaceutical composition containing benzofuran derivatives
DK0926952T3 (da)	2002-07-29	Antimikrobiel sammensætning og fremgangsmåde til fremstilling deraf
NO995500D0 (no)	1999-11-10	Anvendelse av en farmasöytisk sammensetning til behandling av/eller forhindring av ischemi
DK0912613T3 (da)	2003-01-27	Syntetiske polysaccharider, fremgangsmåde til deres fremstilling og farmaceutiske præparater, der indeholder dem
IL127408A0 (en)	1999-10-28	Novel thiazolidone-2 derivatives 4-diketone substituted method for obtaining them and pharmaceutical compositions containing same
ZA982662B (en)	1999-09-30	Solvent system for enhanced penetration of pharmaceutical compounds.
DK0735042T3 (da)	2000-09-18	Maltitolsammensætning og fremgangsmåde til fremstilling deraf
DK0933373T3 (da)	2002-07-01	Terpenoidlactonforbindelser og fremgangsmåder til fremstilling deraf
NO960272L (no)	1996-01-23	Oksatiolaner, fremgangsmåte for deres fremstilling og farmasöytiske preparater som inneholder de samme
DK0946514T3 (da)	2003-08-25	Fremgangsmåde til fremstilling af n-substituerede 3-hydroxypyrazoler
ZA986964B (en)	1999-02-05	Refractory composition for the prevention of alumina clogging
NO20002114L (no)	2000-06-26	Bisykliske forbindelser, fremgangsmÕte for deres fremstilling og farmasøytiske sammensetninger inneholdende dem
DK1023279T3 (da)	2003-07-21	Forbindelser og fremgangsmåde til fremstilling af substituerede 4-phenyl-4-cyanocyclohexansyrer
DK0806949T3 (da)	2003-12-01	Ny farmaceutisk komposition, der indeholder trimebutin, og fremgangsmåde til fremstilling deraf
GB9623962D0 (en)	1997-01-08	Pharmaceutical composition
DK1046719T3 (da)	2004-09-20	D-galactosesammensætning og fremgangsmåde til fremstilling deraf
DK0776328T3 (da)	1999-07-19	8-fluoranthracycliner, fremgangsmåder til fremstilling deraf og farmaceutiske præparater indeholdende dem